Use of cannabinoid receptor antagonists, preferably rimonabant or N-piperidino-5-(4-bromophenyl)-1- (2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, for the preparation of drugs in the treatment and prevention of type-2 diabetes

摘要

Use of cannabinoid receptor antagonists (I), preferably rimonabant or N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole -3-carboxamide, for the preparation of drugs in the treatment and prevention of type-2 diabetes. An independent claim is included for a pharmaceutical composition comprising cannabinoid receptor antagonists and active ingredients. - ACTIVITY : Antidiabetic. - MECHANISM OF ACTION : Cannabinoid receptor antagonists.